Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Tuesday, February 19, 2019
Catalent Pharma Solutions has received The Procter & Gamble Company’s (P&G) highest external business partner recognition, the External Business Partner of the Year Award.
read more
Catalent announced Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca PLC at Catalent’s manufacturing facility in Anagni, Italy.
read more
Wednesday, February 10, 2021
Catalent hadssigned an agreement with Trizell GmbH, to support the manufacturing of Trizell’s Phase 1 cell therapy for the treatment of micro- and macroangiopathies.
read more
Monday, November 02, 2020
Catalent has signed an agreement with Bone Therapeutics to acquire its cell therapy manufacturing subsidiary, Skeletal Cell Therapy Support.
read more
Tuesday, September 19, 2017
Catalent has reached an agreement to acquire Bloomington, Indiana-based Cook Pharmica, an integrated provider of drug substance and drug product manufacturing and related services.
read more
Friday, February 26, 2021
Catalent and Delphi Genetics have entered into a final and definitive agreement whereby Catalent will acquire 100% of the shares of Delphi Genetics.
read more
Wednesday, January 13, 2021
Catalent has entered into a definitive agreement to acquire the manufacturing and packaging operations of Acorda Therapeutics.
read more
Catalent and Paragon Bioservices announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
read more
Friday, December 16, 2022
Catalent announced that it is to establish a new biologics analytical center of excellence in Durham, within North Carolina’s Research Triangle, to offer comprehensive standalone analytical development and testing for biologic drug modalities, ...
read more
Catalent announced a multi-year $350 million investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities. The project will serve the industry’s robust biologics pipeline across ...
read more
Catalent is set to launch its new OneBio Suite for the integrated development, manufacturing, and clinical supply of biologic drugs.
read more
Tuesday, November 13, 2018
Catalent Pharma Solutions announced its plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019.
read more
Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
read more
Wednesday, October 27, 2021
Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced a $230 million expansion project to add three ...
read more
Catalent announced the company will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine, AZD1222.
read more